The anti-inflammatory effects of some FFAR1 agonists (i.e., GW9508 and AS2034178) have been shown in several animal disease models and in inflammatory-based pathologies for which effective therapies have not yet been found [37,38,39]. Here, FFAR1 is linked to glycogen storage disease VI.